A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Completed · Phase 3 · Has a placebo group

Conditions studied: Malignant Melanoma

In brief

To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.

Key facts

Study ID

NCT01689519

Run by

Hoffmann-La Roche

People needed

495

Starts

2013-01-08

Expected to finish

2019-07-21

Last updated by the study team

2022-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with histologically confirmed melanoma, either unresectable stage IIIc or stage IV metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition. Unresectability of stage IIIc disease must have confirmation from a surgical oncologist
• Participants must be naïve to treatment for locally advanced unresectable or metastatic disease (ie, no prior systemic anti-cancer therapy for advanced disease; stage IIIc and IV). Prior adjuvant immunotherapy (including ipilimumab) is allowed
• Documentation of BRAF V600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) using the cobas 4800 BRAF V600 mutation test
• Measurable disease per RECIST v1.1
• Eastern Clinical Oncology Group performance status of 0 or 1
• Consent to provide archival for biomarker analyses
• Consent to undergo tumor biopsies for biomarker analyses
• Life expectancy greater than or equal to (≥) 12 weeks
• Adequate hematologic and end organ function

You may not qualify if…

• History of prior rapidly accelerated fibrosarcoma or mitogen-activated protein kinase pathway inhibitor treatment
• Palliative radiotherapy within 14 days prior to the first dose of study treatment
• Major surgery or traumatic injury within 14 days prior to first dose of study treatment
• Active malignancy other than melanoma that could potentially interfere with the interpretation of efficacy measures. Participants with a previous malignancy within the past 3 years are excluded except for participants with resected basal cell carcinoma or squamous cell carcinoma of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast
• History of or evidence of retinal pathology on ophthalmological examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion, or neovascular macular degeneration
• Uncontrolled glaucoma with intraocular pressure
• Serum cholesterol ≥ Grade 2
• Hypertriglyceridemia ≥ Grade 2
• Hyperglycemia (fasting) ≥ Grade 2
• History of clinically significant cardiac dysfunction
• Participants with active central nervous system (CNS) lesions (including carcinomatous meningitis) are excluded. However, participants are eligible if:
• All known CNS lesions have been treated with stereotactic therapy or surgery, AND
• There has been no evidence of clinical and radiographic disease progression in the CNS for ≥ 3 weeks after radiotherapy or surgery
• Current severe, uncontrolled systemic disease
• History of malabsorption or other condition that would interfere with absorption of study drugs
• Pregnant, lactating, or breast feeding women

Where it is running

• The Angeles Clinic and Research Institute - W LA Office — Los Angeles, California, United States
• University of California Davis Health System — Sacramento, California, United States
• Sutter Pacific Medical Foundation — Santa Rosa, California, United States
• University Of Colorado — Aurora, Colorado, United States
• Florida Cancer Specialists - Broadway — Fort Myers, Florida, United States
• Mount Sinai Medical Center — Miami Beach, Florida, United States
• Orlando Health Inc. — Orlando, Florida, United States
• Northwestern Center For Clinical Research — Chicago, Illinois, United States
• Uni of Kansas Medical Center; Dept of Neurology — Kansas City, Kansas, United States
• U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology — Louisville, Kentucky, United States
• Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology — St Louis, Missouri, United States
• Dartmouth-Hitchcock Medical Center; Department of Medicine — Lebanon, New Hampshire, United States
• Novant Health Oncology Specialists — Winston-Salem, North Carolina, United States
• University Hospitals of Cleveland — Cleveland, Ohio, United States
• St. Luke's University Health network — Bethlehem, Pennsylvania, United States
• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Rhode Island Hospital; Investigational Services — Providence, Rhode Island, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia
• Lake Macquarie Private Hospital — Gateshead, New South Wales, Australia
• Lismore Base Hospital; Cancer Care & Haematology Unit — Lismore, New South Wales, Australia
• Melanoma Institute Australia — North Sydney, New South Wales, Australia
• Princess Alexandra Hospital — Woolloongabba, New South Wales, Australia
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.